Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2886721 in a · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY2886721 Capsule (water, fasting) | EXPERIMENTAL | Reference formulation. A single oral dose of 70 milligrams (mg) LY2886721 in a capsule given with water and without a meal in one of four periods. |
| LY2886721 ODT (no water, fasting) | EXPERIMENTAL | A single oral dose of 70 mg LY2886721 in an orally disintegrating tablet (ODT) given without water and without a meal in one of four periods. |
| LY2886721 ODT (water, fed) | EXPERIMENTAL | A single oral dose of a 70 mg LY2886721 in an orally disintegrating tablet (ODT) given with water and after a high-fat breakfast in one of four periods. |
| LY2886721 ODT (water, fasting) | EXPERIMENTAL | A single oral dose of 70 mg LY2886721 in an orally disintegrating tablet (ODT) given with water and without a meal in one of four periods. |
| Name | Type | Description |
|---|---|---|
| LY2886721 in a Capsule | DRUG | Administered orally. |
| LY2886721 in an orally disintegrating tablet (ODT) | DRUG | Administered orally. |
Inclusion Criteria: * Have a body mass index (BMI) of 18.5 to 32.0 kilograms per square meter (kg/m\^2), inclusive, at screening * At least 4 participants who are greater than 55 years of age * Male participants: Agree to use a reliable method of birth control and not donate sperm during the study ...
LY2886721 is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and is in early clinical development. The completed Phase 1 trial evaluated the drug in healthy participants to assess its safety and tolerability.
LY2886721 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker symbol LLY. The company sponsored the clinical trial of this investigational drug.
LY2886721 is in Phase 1 clinical development. The single trial listed for this drug is a completed Phase 1 study. As an investigational drug, it has not been approved by regulatory authorities and remains in clinical testing.
LY2886721 has one completed clinical trial, identified as NCT01775904, titled "A Study of Two Dosage Forms of LY2886721 in Healthy Participants." This Phase 1 study enrolled 26 participants in the United States and evaluated the drug in healthy volunteers.
LY2886721 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial in healthy volunteers. The drug is still in clinical development and has not been authorized for marketing or use in any disease.